DBV Technologies (DBVT) Change in Accured Expenses (2020 - 2026)
DBV Technologies (DBVT) posted quarterly Change in Accured Expenses of $3.1 million for Q2 2026, up 93.75% year-on-year from $1.6 million in Q2 2025, and up 165.96% on a QoQ basis from -$4.7 million in Q1 2026.
DBV Technologies (DBVT) Change in Accured Expenses (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Change in Accured Expenses for 7 consecutive years, with $3.1 million the latest figure, recorded in Q2 2026.
- Quarterly Change in Accured Expenses rose 93.75% year-over-year to $3.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $6.4 million (up 344.98% YoY) and the FY2025 annual result came in at $6.5 million, up 1681.69% from the prior year.
- Change in Accured Expenses grew to $3.1 million in Q2 2026 per DBVT's latest filing, from -$4.7 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for DBVT reached as high as $7.2 million in Q4 2025 and fell as low as -$4.7 million in Q1 2026.
- A 5-year average of $5833.3 and a median of $603500.0 in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses plunged 178.35% — and 2024, when it soared 1463.16%.
- Year by year, Change in Accured Expenses stood at $3.6 million in 2022, then tumbled by 178.35% to -$2.8 million in 2023, then soared by 157.09% to $1.6 million in 2024, then surged by 351.29% to $7.2 million in 2025, then plunged by 56.82% to $3.1 million in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $3.1 million, -$4.7 million, and $7.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -16.82 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -16.74 Mn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | 3.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.10 Mn |
| Jun 30, 2026 | 3.10 Mn |
| Mar 31, 2026 | -4.70 Mn |
| Mar 31, 2026 | -4.70 Mn |
| Dec 31, 2025 | 7.18 Mn |
| Dec 31, 2025 | 7.18 Mn |
| Sep 30, 2025 | 841,000.00 |
| Sep 30, 2025 | 841,000.00 |
| Jun 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 1.60 Mn |
| Mar 31, 2025 | -3.10 Mn |
| Mar 31, 2025 | -3.10 Mn |
| Dec 31, 2024 | 1.59 Mn |
| Dec 31, 2024 | 1.59 Mn |
| Sep 30, 2024 | 1.35 Mn |
| Sep 30, 2024 | 1.35 Mn |
| Jun 30, 2024 | 1.19 Mn |
| Jun 30, 2024 | 1.19 Mn |
| Mar 31, 2024 | -3.77 Mn |
| Mar 31, 2024 | -3.77 Mn |